跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 10,526 条关于
“Nelivabon (BH-200)”
全部
10,526
临床试验
5,166
药物
2,852
机构
25
资讯
2,483
3个月前
HMNC Brain Health Secures $50 Million Series B Financing and European Partnership with MEDICE for Precision Psychiatry Pipeline
去年
HMNC Brain Health Completes Patient Randomization in Phase 2b Trial of BH-200 for Major Depressive Disorder
去年
HMNC Brain Health's BH-200 Shows Promising Results in Phase 2 Depression Trial with Genetic Selection Tool
前天
BlossomHill's OMNI-EGFR Inhibitor BH-30643 Yields 45% ORR in C797S-Positive NSCLC
去年
BlossomHill Therapeutics to Present Novel OMNI-EGFR Inhibitor BH-30643 at AACR 2025 for NSCLC Treatment
去年
BlossomHill Therapeutics Advances EGFR-Mutant NSCLC Treatment with First-in-Class OMNI-EGFR Inhibitor BH-30643
6个月前
BlossomHill Therapeutics Unveils Next-Generation Pan-KRAS Inhibitors with Picomolar Potency at AACR 2026
9个月前
BlossomHill Therapeutics Secures $84 Million to Advance First-in-Class EGFR Inhibitor for Lung Cancer
2个月前
BlossomHill Therapeutics Files for $100M Nasdaq IPO to Advance Macrocyclic Cancer Pipeline
4个月前
UCB Opens €200 Million Gene Therapy Manufacturing Facility in Belgium
第 1 页,共 249 页
上一页
下一页